骨髓纤维化与骨髓增生异常综合征贫血的新兴发病机制及新药
该综述阐述髓系肿瘤贫血涉及无效造血、铁调素介导的铁限制性造血及炎症细胞因子异常等多重机制,现有特异性药物有限;新型疗法靶向TGF-β-BMP-SMAD通路,包括配体陷阱、ACVR1/ALK2抑制剂和抗血幼素抗体等,其中罗特西普、莫莫替尼和伊美司他已获批用于相应贫血适应症,联合策略与SGLT-2抑制剂的应用前景值得探索。
要点
- 骨髓纤维化和骨髓增生异常综合征贫血机制包括无效造血、铁调素介导的铁限制性造血和炎症细胞因子异常。
- 罗特西普和莫莫替尼分别获批用于较低危骨髓增生异常综合征和骨髓纤维化相关贫血,伊美司他亦获批用于较低危骨髓增生异常综合征贫血。
- 靶向TGF-β-BMP-SMAD通路的在研药物包括elritercept、zilurgisertib和DISC-0974等。
核心结论
- 罗特西普和莫莫替尼分别获批用于较低危骨髓增生异常综合征和骨髓纤维化相关贫血,伊美司他近期获批用于较低危骨髓增生异常综合征贫血。
- 药物联合策略与利用SGLT-2抑制剂促红细胞生成潜力是克服现有贫血治疗局限的有前景策略。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 贫血机制涉及无效造血、铁调素诱导的铁限制性造血和异常炎症细胞因子产生。
- TGF-β-BMP-SMAD通路在无效造血(SMAD 2/3)和异常铁调素产生(SMAD 1/5/8)中起重要作用。
- 新型疗法包括TGF-β配体陷阱(罗特西普、elritercept)、ACVR1/ALK2抑制剂(莫莫替尼、zilurgisertib)和抗血幼素抗体疗法(DISC-0974)。
- 有前景的策略包括互补机制药物联合(罗特西普+红细胞生成刺激剂、罗特西普+莫莫替尼、DISC-0974+莫莫替尼)以及利用SGLT-2抑制剂的促红细胞生成潜力。
关键数值与推荐
- 罗特西普获批用于较低危骨髓增生异常综合征相关贫血。
- 莫莫替尼获批用于骨髓纤维化相关贫血。
- 伊美司他近期获批用于较低危骨髓增生异常综合征贫血。
临床怎么用
- 罗特西普、莫莫替尼和伊美司他已获批用于相应贫血适应症,代表贫血治疗武器库的重要补充。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anemia in myeloid neoplasms is multifaceted, with heterogeneous pathogenetic mechanisms that include ineffective erythropoiesis, hepcidin-induced iron-restricted erythropoiesis, and abnormal inflammatory cytokine production. Current management of anemia is challenged by limited approved drugs that specifically treat anemia in myelofibrosis (MF) and myelodysplastic syndrome (MDS). Newer therapies target the transforming growth factor beta (TGF-β)-bone morphogenic protein/sons of mothers against decapentaplegic (BMP-SMAD) signaling pathway, which plays a significant role in ineffective erythropoiesis (SMAD 2/3) and abnormal hepcidin production (SMAD 1/5/8). These include TGF-β ligand traps (luspatercept, elritercept), activin A receptor type 1 (ACVR1)/activin receptor-like kinase 2 (ALK2) inhibitors (momelotinib, zilurgisertib), and anti-hemojuvelin antibody-based therapies (DISC-0974). Luspatercept and momelotinib are approved for anemia related to lower-risk MDS and MF, respectively, and represent an important addition to the treatment armamentarium, along with imetelstat, a telomerase inhibitor, recently ratified for anemia in lower-risk MDS. A promising strategy to overcome the limitations of existing anemia-directed therapies includes the use of drug combinations with complementary mechanisms (luspatercept + erythropoiesis stimulating agents, luspatercept + momelotinib, DISC-0974 + momelotinib), and harnessing the erythropoietic potential of sodium-glucose co-transporter-2 inhibitors (SGLT-2I). Future research should address the complex pathophysiology of anemia, standardize definitions for anemia with gender-specified cutoffs, implement uniform erythroid response criteria, and consider early therapeutic intervention in clinical trials for anemia-directed therapies.
引用
- Gangat N, Tefferi A. Emerging Pathogenetic Mechanisms and New Drugs for Anemia in Myelofibrosis and Myelodysplastic Syndromes. Am J Hematol. 2025. PMID: 40056069. doi:10.1002/ajh.27659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。